Johnson & Johnson $JNJ Shares Bought by Braun Stacey Associates Inc.

Braun Stacey Associates Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 153,148 shares of the company’s stock after buying an additional 4,292 shares during the quarter. Johnson & Johnson accounts for 1.2% of Braun Stacey Associates Inc.’s investment portfolio, making the stock its 20th largest holding. Braun Stacey Associates Inc.’s holdings in Johnson & Johnson were worth $37,435,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after buying an additional 3,731,074 shares during the period. State Street Corp boosted its stake in shares of Johnson & Johnson by 1.3% in the fourth quarter. State Street Corp now owns 133,869,843 shares of the company’s stock valued at $27,704,364,000 after buying an additional 1,663,782 shares in the last quarter. Auto Owners Insurance Co grew its holdings in Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares during the period. Geode Capital Management LLC raised its position in Johnson & Johnson by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock worth $11,967,947,000 after acquiring an additional 1,738,292 shares in the last quarter. Finally, Norges Bank purchased a new position in Johnson & Johnson in the fourth quarter worth $6,924,523,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on JNJ shares. Argus boosted their target price on shares of Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. The Goldman Sachs Group increased their price target on shares of Johnson & Johnson from $265.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday, April 15th. Raymond James Financial raised their price objective on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Stifel Nicolaus boosted their price objective on shares of Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, April 15th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $265.00 target price on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.70.

Johnson & Johnson Trading Up 1.4%

NYSE:JNJ opened at $258.24 on Tuesday. Johnson & Johnson has a 52-week low of $151.52 and a 52-week high of $258.58. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The stock has a fifty day simple moving average of $231.39 and a 200-day simple moving average of $230.03. The company has a market capitalization of $621.65 billion, a PE ratio of 29.85, a price-to-earnings-growth ratio of 2.49 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion for the quarter, compared to analysts’ expectations of $23.60 billion. During the same period in the prior year, the company earned $2.77 EPS. The firm’s revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities research analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were given a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is 61.97%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received a positive CHMP opinion for expanded use of its multiple myeloma drug Tecvayli in combination with Darzalex SC, which could broaden the treatment’s commercial opportunity if approved. Article Title
• Positive Sentiment: JNJ hit a new 52-week high as biotech shares rallied, with investors favoring large-cap healthcare names that have visible pipelines, approvals, and deal-related momentum. Article Title
• Positive Sentiment: Analysts highlighted JNJ’s recent share strength and noted that upward earnings estimate revisions could support additional near-term gains. Article Title
• Positive Sentiment: Johnson & Johnson won another talc-related lawsuit, with a Los Angeles jury finding the company was not negligent in a case involving ovarian cancer claims. Article Title
• Positive Sentiment: Guggenheim raised its price target on JNJ to $270 and reiterated a Buy rating, reflecting continued confidence ahead of the company’s upcoming earnings season. Article Title
• Neutral Sentiment: Commentary about JNJ’s dividend appeal and healthcare sector strength reinforces its status as a stable income stock, but does not add a new fundamental catalyst on its own. Article Title

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.